Q&A: Putting the New Melanoma Drugs to Work
Dr. Paul Chapman, Dr. Jedd Wolchok, Dr. Vernon K. Sondak, and Dr. Alexander M.M. Eggermont discuss how they will use vemurafenib and ipilimumab.
August 17, 2011|Dermatology
Author and Disclosure Information
FROM THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY
Dr. Eggermont: I think you need to separate the new drugs from the question, what are we going to do in adjuvant? In adjuvant right now, we will still have to wait for about 2.5-3 years for the outcome of the EORTC trial that randomized in double-blind ipilimumab vs. observation in patients with high-risk lymph node positive disease. That answer about ipilimumab in the adjuvant situation will not be there before 2.5 years from now. That means that until then there is only one kid on the block in the adjuvant setting, which is regular interferon, and the currently novel approach of pegylated interferon.
